COMMUNIQUÉS West-GlobeNewswire

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
04/08/2026
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access [...]
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
04/08/2026
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s investigational FAK inhibitor narmafotinib in combination with Lilly’s [...]
Cannabix Targets Combat Sports Market for Commercial Rollout of Marijuana Breath Test at ABC Boxing & MMA Conference
04/08/2026
VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing [...]
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
04/08/2026
Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
04/08/2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights
04/08/2026
Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5% Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth First half revenue of $54.4M, +44% year-over-year growth; [...]
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
04/08/2026
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic [...]
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
04/08/2026
11 tissue, blood, and cerebrospinal fluid biomarkers reflecting the biological cascade of neurodegeneration and neuroinflammation in PD respond in concert to risvodetinib treatment in patients with early untreated [...]
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
04/08/2026
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga [...]
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators
04/08/2026
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of [...]
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
04/08/2026
Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development [...]
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
04/08/2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
04/08/2026
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~ SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), [...]
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
04/08/2026
RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Exagen Inc. Reports Second Quarter 2026 Financial Results
04/08/2026
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million [...]
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
04/08/2026
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patients Study confirms LTI-03 was safe and well- [...]
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
04/08/2026
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference [...]
FDA clears Healis Therapeutics’ IND for Tyemvers®, Enabling U.S. Neuropsychiatric Trials
04/08/2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Healis Therapeutics announced that it has opened an IND with the U.S. FDA for Tyemvers®, a new botulinum toxin type A product. The milestone enables Healis to initiate [...]

Pages